Determination of Pancreatic Steatosis Prevalence and Correlation With High-risk Cyst Features

Plain-language summary

This study investigates the prevalence of fat accumulation in the pancreas (pancreatic steatosis) and its relationship to high-risk pancreatic cyst features, using MRI that measures pancreatic and liver fat. It enrolls patients aged 18 and over who have at least one pancreatic cyst (presumed IPMN or MCN, at least 5 mm), or healthy volunteers. This is a study without a phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Recruiting

Sponsor

Chinese University of Hong Kong

Intervention

MRI for pancreatic fat and liver fat quantitation

Start date

4/6/2022

Estimated completion

4/30/2026

Countries

Hong Kong

Related genes

Locations

• Shatin, Hong Kong

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

1. Age 18 or older
2. Patients with at least 1 pancreatic cystic lesion presumed to be IPMN or MCN based on CT, MRI or EUS features, with a cyst size ≥ 5mm; or healthy subjects.
3. Patients who are able to provide written informed consent to participate in the study and comply with the study procedures.

Exclusion Criteria:

1. Unable to provide written informed consent
2. Patients with metallic implants or other contraindications to MRI
3. Patients with contraindications for endoscopy due to comorbidities
4. Patients with known pancreatic cancer or prior pancreatic resection
5. Patients with significant alcohol consumption, defined as alcohol intake of over 20 g daily (140 g weekly) for men and 10 g daily (70 g weekly) for women